Outcomes* · chronic bronchitis or COPD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participants with no exacerbations in study period · chronic bronchitis or COPD
Mucolytic probably leads to higher participants with no exacerbations in study period compared with placebo (moderate certainty).
1 finding from 1 review
Days of disability per participant per month · chronic bronchitis or COPD
1 finding from 1 review
SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · chronic bronchitis or COPD
1 finding from 1 review
Hospitalisation during study period · chronic bronchitis or COPD
Mucolytic probably leads to lower hospitalisation during study period compared with placebo (moderate certainty).
1 finding from 1 review
FEV₁at end of study · chronic bronchitis or COPD
1 finding from 1 review
Adverse effects · chronic bronchitis or COPD
Mucolytic probably leads to lower adverse effects compared with placebo (moderate certainty).
1 finding from 1 review
Death during study period · chronic bronchitis or COPD
Mucolytic showed no clear difference in death during study period compared with placebo (moderate certainty).
1 finding from 1 review
Psychophysical testing for recovery of sense of smell · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
It is very uncertain whether systemic corticosteroids plus intranasal… changes psychophysical testing for recovery of sense of smell compared with no intervention (very low certainty).
1 finding from 1 review
Disease‐related quality of life · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
1 finding from 1 review
Change in sense of smell · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
1 finding from 1 review
Generic quality of life measures · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Presence of parosmia · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Other adverse outcomes · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
1 finding from 1 review
Frequency and duration of exacerbations · people with bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events · people with bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
Health‐related quality of life · people with bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
Symptoms sputum colour Scale used not reported · people with bronchiectasis
RhDNase showed no clear difference in symptoms sputum colour Scale used not reported compared with placebo (low certainty).
1 finding from 1 review
Deaths · people with bronchiectasis
RhDNase showed no clear difference in deaths compared with placebo (low certainty).
1 finding from 1 review